Search
Descriptor English: Lapatinib
Descriptor Spanish: Lapatinib
Descriptor lapatinib
Entry term(s) GW 282974X
GW 572016
GW-282974X
GW-572016
GW282974X
GW572016
N-(3-cloro-4-(((3-fluorobencil)oxi)fenil)-6-(5-(((2-metilsulfonil)etil)amino)metil)-2-furil)-4-quinazolinamina
ditosilato de lapatinib
tykerb
Scope note: Derivado quinazolínico que inhibe la tirosina-cinasa del RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO y del HER2 (RECEPTOR ERBB-2). Se usa para el tratamiento del cáncer de mama avanzado o metastásico con sobreexpresión de HER2.
Descriptor Portuguese: Lapatinib
Descriptor French: Lapatinib
Entry term(s): GW 282974X
GW 572016
GW-282974X
GW-572016
GW282974X
GW572016
Lapatinib Ditosylate
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
Tykerb
Tree number(s): D03.633.100.786.516
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000077341
Scope note: A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents
Protein Kinase Inhibitors
Registry Number: 0VUA21238F
Public MeSH Note: 2019; LAPATINIB was indexed under QUINAZOLINES 2004-2018
History Note: 2019 (2004)
DeCS ID: 57625
Unique ID: D000077341
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2018/07/03
Lapatinib - Preferred
Concept UI M0473129
Scope note A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
Preferred term Lapatinib
Entry term(s) N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
Tykerb - Narrower
Concept UI M0498282
Preferred term Tykerb
GW 282974X - Narrower
Concept UI M0505242
Preferred term GW 282974X
Entry term(s) GW-282974X
GW282974X
GW572016 - Narrower
Concept UI M0463676
Preferred term GW572016
Entry term(s) GW 572016
GW-572016
Lapatinib Ditosylate - Narrower
Concept UI M0473529
Preferred term Lapatinib Ditosylate



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey